KRIYA 825
Alternative Names: KRIYA-825Latest Information Update: 14 Feb 2024
At a glance
- Originator Kriya Therapeutics
- Class Eye disorder therapies; Gene therapies; Recombinant fusion proteins
- Mechanism of Action Complement C3 expression inhibitors; Complement C5 expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Dry age-related macular degeneration